Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference Back Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference Read More
Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference Back Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference Read More
Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas Back Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas Read More
Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split Back Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split Read More